Get started
Author

Anita Csizmarik

Observed names: A Csizmarik, A. Csizmarik, Csizmarik A, Csizmarik Anita, Csizmarik, Anita
Observed institution: Semmelweis University
ORCID: 0000-0001-8394-3722
Observed ORCID: 0000-0001-8394-3722
OpenAlex ID: A5041123794
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
2021 · Ulrich Krafft, Csilla Olah, et al. · Cancers · 46
PDF
Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer
2020 · Tibor Szarvas, Anita Csizmarik, et al. · British Journal of Urology · 38
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
2022 · Ádám Széles, Tamás Fazekas, et al. · Cancer Immunology Immunotherapy · 31
PDF
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas
2023 · Melinda Varadi, Nikolett Nagy, et al. · Cancer Medicine · 18
PDF
Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer
2021 · Anita Csizmarik, Boris Hadaschik, et al. · Urologic Oncology Seminars and Original Investigations · 18
PDF
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
2020 · Tibor Szarvas, Michèle J. Hoffmann, et al. · Diagnostics · 18
Prevalence of APC and PTEN Alterations in Urachal Cancer
2020 · Nikolett Nagy, Henning Reis, et al. · Pathology & Oncology Research · 17
PDF
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis
2023 · Tamás Fazekas, Ádám D. Széles, et al. · European Urology Oncology · 16
PDF
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer
2018 · Christopher Darr, Ulrich Krafft, et al. · Urologia Internationalis · 14
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
2022 · Tamás Fazekas, Ádám D. Széles, et al. · Prostate Cancer and Prostatic Diseases · 11
PDF
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
2020 · T. Szarvas, A. Csizmarik, et al. · Urologic Oncology Seminars and Original Investigations · 11
PDF
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
2020 · Csilla Olah, Stephan Tschirdewahn, et al. · Diagnostics · 10
PDF
A prosztatarák molekuláris altípusai és célzott terápiás kilátásai
2019 · Tibor Szarvas, Anita Csizmarik, et al. · Orvosi Hetilap · 10
PDF
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration‐resistant prostate cancer
2018 · Tibor Szarvas, Sabina Sevcenco, et al. · British Journal of Urology · 9
PDF
Precision Oncology Approach for Urachal Carcinoma: A Clinical Case Report
2024 · Dániel Juhász, Anita Csizmarik, et al. · International Journal of Molecular Sciences · 7
PDF
Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis
2023 · András Kubik, Isabel Pinto Amorim das Virgens, et al. · International Journal of Molecular Sciences · 7
PDF
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer
2021 · Dávid Keresztes, Anita Csizmarik, et al. · Journal of Cellular and Molecular Medicine · 7
PDF
Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer
2024 · Teemu J. Murtola, Aino Siltari, et al. · European Urology Open Science · 6
Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma
2025 · M. Váradi, O. Horváth, et al. · Cancer Immunology Immunotherapy · 5
PDF
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
2022 · Petra Terézia Kovács, Tamás Mayer, et al. · Biomedicines · 5
PDF
Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer
2022 · Anita Csizmarik, Dávid Keresztes, et al. · International Journal of Cancer · 4
PDF
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
2022 · Ádám Széles, Petra Terézia Kovács, et al. · Biomedicines · 3
PDF
COVID-19 research: promising tracks leading to uro-oncology
2020 · Fazekas Tamás, Szarvas Tibor, et al. · International Urology and Nephrology · 3
PDF
Az áttétes kasztrációrezisztens prosztatarák gyógyszer-rezisztenciájának molekuláris vonatkozásai
2020 · Tibor Szarvas, Anita Csizmarik, et al. · Orvosi Hetilap · 3
PDF
High-soluble CGA levels are associated with poor survival in bladder cancer
2019 · T Szarvas, B Jardin-Watelet, et al. · Endocrine Connections · 3
PDF
Works count: 63
Citation count: 329
H-index: 11
I10-index: 13
Year
Topic
Type